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ABSTRACT 
Background: Colorectal cancer (CRC) is a common global disease, with a mortality 
rate of almost 50%. Prognosis is mainly based on the TNM classification. Surgical 
interventions have the potential of being curative in patients with stage I-III CRC. 
Adjuvant treatment with chemotherapy enhances the survival rate, especially in stage 
III cancer. Chemotherapy does, however, have significant side effects. Therefore, 
refinement of therapies based on improved prognostic ability on an individual level is 
essential. One way to achieve this could be to examine the tumours on a molecular 
level and not just histologically. Recent studies have shown that K-ras mutation is a 
negative predictor to anti-EGFR (epidermal growth factor receptor) therapy. 
MicroRNAs were discovered only 2 decades ago but are now the most promising 
biomarkers in many cancers. In this thesis, the first two papers focus on genetic 
changes in the tumour and in lymph nodes, in particular looking at the oncogene K-ras. 
The last two papers focus on microRNAs in tumours and in blood serum. In studies 2, 3 
and 4, our findings on the correlation of some molecular changes to prognosis is 
described. 
Study I:  
17 tumours from CRC patients were divided in to small cubes. DNA was extracted 
from each biopsy and the occurrence of K-ras mutations, methylation of p16 and 
MGMT, and loss of heterozygosity (LOH) at 5q, 17p and 18q were analysed. 
We found that the distribution of methylated p16 and MGMT and LOH at 5q, 17 p and 
18q are heterogeneous and present in a large majority of CRC tumours, thereby of 
limited prognostic value. However, K-ras mutation appears more homogeneously 
spread, a finding of clinical relevance for the use of biopsies to predict anti-EGFR 
response. 
Study II: 
99 stage II CRC patients with histologically normal lymph nodes were included. DNA 
was extracted from lymph nodes, tumours and normal mucosa and the K-ras status was 
analysed and correlated to prognosis. 
Of the tumours, 34/99 were identified as positive for K-ras mutations. Of these, 10 
patients also expressed K-ras mutations in their lymph nodes. Of the 10 patients with 
positive lymph nodes, 7 (70%) relapsed and died from the disease within 60 months 
compared to 8/ 24 (33%) with K-ras negative lymph nodes. 
Study III: 
50 CRC patients were studied. RNA was extracted from the tumours. 5 patients with 
short and 5 patients with long survival were selected for SYBR-green quantitative 
PCR-based array to screen for differently expressed microRNAs. From this screening, 
6 candidate prognostic microRNAs were validated using TaqMan quantitative PCR in 
all 50 patients. 
We found that high expression of miR-185 and low expression of miR-133b correlated 
to poor survival (p=0.001 and p=0.028, respectively) and metastasis (p=0.007 and 
p=0.036, respectively) in CRC. 
 
 
 
 
  
Study IV: 
16 CRC patients and one with a large adenoma in the colon were included. All patients 
underwent radical (R0) surgery. Blood serum was collected prior to and 30 days after 
surgery. 3 microRNAs were analysed with Taqman qPCR (miR-21, miR-133b and 
miR-185). 
The serum levels of mir-21 were not affected by radical tumour resection. There was a 
significant decrease in the level of miR-133b among the patients following surgery, and 
an overall reduction of miR-185. There was no correlation between intra-individual 
changes in serum levels pre- and postoperatively to disease outcome, or between 
baseline levels and the risk of recurrent disease.  
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FOREWORD 
 
 
 
 
Colorectal cancer (CRC) is a complex disease process. The basic aetiology begins 
within a normal epithelium cell, in the colon- or rectal mucosa, which transforms and 
develops into a tumour cell, eventually becoming malignant. There are varying grades 
of cell dysplasia depending on the stage of disease process. Despite improvements in 
diagnosis, surgical techniques, and chemotherapeutic regimens, CRC is still responsible 
for many deaths around the world. The work in this thesis focuses on studying several 
genetic events involved in, or consequences of, CRC. The purpose was to investigate 
their relationship to disease outcome, with the aim to study their usefulness in 
improving diagnosis and prognostic accuracy, thereby refining the possibility of 
applying correct treatment modalities in the individual patient.  
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1 Background 
 
Epidemiology 
Colorectal cancer (CRC) is the third most common cancer in men and the second most 
common cancer in women worldwide (1). In 2010, the Swedish National Board of 
Health and Welfare reported that colon cancer is the third most common cancer in 
Sweden irrespective of gender. The incidence for colon cancer in Sweden is 
approximately 4000 new cases per annum, and that of rectal cancer is approximately 
2000 cases per annum. With a mortality of about 50%, 0.6 million will succumb to the 
disease of the estimated 1.23 million individuals affected worldwide annually. Notably 
the disease is more common in more developed countries than in lesser developed 
countries (2). The 5-year survival rates range from 90% to 10% depending on tumour 
progression (3). The 5-year cumulative rate for distant metastasis in Stage I, II and III 
(staging is described in more detail below) are 6.4, 21.4 and 48.0 per cent respectively 
(4). Altogether this is a common and deadly disease that requires early diagnosis and 
treatment to improve prognosis. 
 
Risk factors 
Most cancers are believed to develop by a combination of genetic and environmental 
factors. Since the disease is more common in more developed countries, many 
researchers have investigated environmental risk factors. It has been postulated that it 
takes one generation for a family that moves from one country to another to exhibit the 
same cancer rates as in the new environment, thereby supporting this theory of 
environmental modulation (5). One of the possible explanations may be due to 
environmental carcinogens related to industrial bi-products and synthetic products in 
more developed countries. Other contributing factors include a diet rich in unsaturated 
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fats and red meat, high total energy intake, excessive alcohol consumption and reduced 
physical activity, which have all been shown to enhance the risk of CRC (6, 7). 
 
Interestingly, non steroidal anti-inflammatory drugs (NSAIDs), calcium and oestrogen 
appear to protect against CRC (7, 8). Patients with inflammatory bowel diseases have 
also been shown to be at a greater risk of developing CRC (9). The aetiology of CRC is 
complex and multi-factorial and the role of intestinal flora is still unclear. Intestinal 
flora may contribute to both increased and decreased risks of developing CRC 
depending on the composition. Thus several studies are being conducted to define 
different types of gut flora and their impact on intestinal function and subsequent 
disease development (10, 11). 
 
Staging 
Staging and prognosis is mainly based on the Tumour Nodules Metastasis (TNM) 
classification according to International Union Against Cancer (IUAC), and the 
American Joint Committee on Cancer (AJCC), as outlined in Table 1. The pathological 
anatomical diagnosis (PAD) is performed by a qualified pathologist under microscopic 
examination. To be able to stage the cancer, several histological questions need to be 
answered; for example, the number of lymph nodes (at least 12 lymph nodes is 
considered a minimal requirement), degree of differentiation of the tumour, venous and 
lymphatic invasion, and nerve infiltration. The TNM classification has been regularly 
updated and modified since it first was established. Today, the tumour infiltration 
evaluation is more precise and there are several subgroups in the different stages.  
 
The basis for the utilization of adjuvant therapies, in addition to surgery, depends on the 
histological evaluation and the TNM classification of the tumour. Due to limitations of 
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using TNM as the only prognostic variable in clinical practice the consequence may be 
a certain degree of over-treatment of patients in advanced stages and, reciprocally, 
omission of a number of patients in earlier stages that may benefit from adjuvant 
therapy. 
 
Table 1. Simplified TNM classification 
 Tumour Nodules Metastasis 
Stage I/ 
Duke´sA 
T1-tumour invades 
submucosa 
T2-tumour invades 
muscularis propria 
N0=no lymph 
node involvement 
M0=no distant 
metastasis 
Stage II/ 
Duke´sB 
T3-tumour invades through  
m propria into the subserosa 
T4- tumour invades other 
organs or structures 
N0 M0 
StageIII/ 
Duke´sC 
T1-T4 N1-2=lymph node 
involvement 
M0 
 
Stage IV T1-T4 N0-N2 M1=distant 
metastasis present 
 
 
Treatment 
Three different modalities are currently used in the treatment of colorectal cancer: 
surgery, chemotherapy, and radiation therapy, and in many cases a combination of 
these. The results of surgical treatment have improved over the last few decades by 
implementation of the total mesorectal excision (TME) technique used in rectal cancer. 
The similar surgical approach has recently been adapted to colon cancer (12,13). The 
introduction of „high ties‟ and higher yields of lymph node extraction in the specimen, 
have also improved outcome (14-16). Radiation therapy used as a target specific 
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treatment modality in rectal cancer, preoperatively exposing the tumour mass to highly 
focused high energy beams of radiation, further has improved outcome (17). Radio 
therapy is also used in some cases on distinct metastases. Adjuvant pharmaceutical 
therapies are both cytotoxic and biologic; namely: 5-FU (fluorouracil), bevacizumab, 
leucovorin, cetuximab, oxaliplatin and irinotecan. Over the decades, adjuvant therapies 
have progressively improved outcome in CRC patients. Today, some genetic mutations 
are also clinically important factors in the allocation of treatment modalities. The 
mutational  status of the K-ras gene is a predictor of the outcome of anti-epidermal 
growth factor receptor (EGFR) treatment of metastatic CRC with the chemotherapeutic 
agent cetuximab (18-20).Furthermore, MSI status is a negative predictor of 5-FU 
treatment (21). These predictive tests are pioneering the utilization of genetic events 
that can tailor treatment regimen in a more precise manner based on factors beyond 
microscopic classification.  
 
Familial cancer 
Familial or inherited cancer is characterized by a germ line mutation which increases 
the susceptibility to acquire somatic mutations, eventually leading to cellular dysplasia 
and the development of cancer (22). In colorectal cancer the two most common familial 
disorders are the familial adenomatous polyposis, caused by a mutation in the APC 
gene, and HNPCC (hereditary non polyposis colon cancer), also known as Lynch 
disease, which is caused by a mutation in one of the mismatch repair genes (23). The 
work in this thesis is focused on sporadic cases of colorectal cancer, and excluded 
patients with known germ line mutations. Also in sporadic cases of the disease, 
mutations in the APC gene and mismatch repair genes can be seen. Thus it is important 
to note that genetic studies on the familial cancer cells and germ line cells have 
improved the understanding of tumorigenesis even in sporadic cases. 
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Tumorigenesis 
As mentioned above, the development of colorectal cancer is a complex, heterogeneous 
and multi-factorial process. It may possibly start with one mutation in an epithelial cell, 
but, after several stepwise mutations, the neoplastic cell will eventually become 
malignant. Vogelstein and Fearon first described this “Vogelgram” pattern of 
tumorigenesis (24,25).  This model proposes an accumulation of mutations that initially 
change the normal epithelium to an adenoma and then into a carcinoma, (Figure 1). The 
model has been modified throughout the years, and is still being updated with the 
discovery of new key elements in tumour development. 
 
Figure 1. A modified “Vogelgram”.  Multi-step genetic mutations eventually leading to 
the development of cancer. Suggested deregulations of microRNAs are also shown. 
 
 
The molecular defects are of two types: (i) alterations that lead to novel or increased 
function of oncogenes, and, (ii) alterations that lead to loss of function of tumour-
suppressor genes (7). A malignant epithelial cell does not respect the epithelial 
membrane thus leading to eventual tumour invasion in to the surrounding structures. 
Furthermore, once the malignant process has begun, the cell escapes apoptosis and 
becomes immortalized. The abilities of the cancer cell to metastasize are induced when 
it acquires traits such as motility and can adapt to foreign environments, enabling it to 
survive in different tissue environments in the body.  
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Intra- and extracellular communication are essential in the normal functioning of the 
cell and tissue growth. The epithelial cells communicate through a multitude of 
different factors and receptors. When a receptor is activated in the cell membrane it 
starts an intracellular signalling cascade, eventually leading to the activation of 
transcription factors. Through the activation of these factors different cellular behaviour 
is accomplished, including apoptosis, migration, growth, adhesion and differentiation.  
In tumorigenesis, intracellular overactivation of a growth factor may result in 
uncontrolled proliferation, and this result from a combination of abnormal genetic and 
epigenetic events.  
In carcinomas, extracellular communication with stromal cells, such as fibroblasts, 
myofibroblasts, and endothelial cells is crucial as these cells are recruited for various 
types of physiological support. This interdependence is manifested by the exchange of 
various types of mitogenic and trophic factors, for example PDGF (platelet derived 
growth factor), IGF (insulin-like growth factor) and VEGF (vascular endothelial 
growth factor) (5).  
 
Currently, it is believed that there are three key pathways in the development of CRC: 
CIN (chromosomal instability), MSI (microsatellite instability), and CIMP (CpG island 
methylation phenotype). These pathways may work independent of one another, or 
they may overlap resulting in a multiple mutational aetiology. Details of the pathways 
are as discussed below.  
 
 
 
 
 
 
 8 
CIN (chromosomal instability) 
CIN is a type of genomic instability where changes in the chromosomal copy numbers 
and structure occur. In CRC, the CIN pathway leads to aneuploidy, in turn causing 
genetic instability and an increased rate of mutations. Further, parts of a chromosome 
may be lost, (LOH, loss of heterozygosity, discussed below) which may result in the 
losing a tumour suppressor gene, allowing for uncontrolled cellular growth (26,27).  
 
Microsatellite instability (MSI) 
Microsatellites are repeated sequences of normal untranscribed DNA throughout the 
genome. In case a mismatch repair gene (MMR gene) becomes mutated, as in HNPCC, 
or silenced by methylation, microsatellites accumulate replication errors and become 
longer or shorter, i.e. they become instable. In sporadic CRC this can be seen in 
approximately 15% of cases. The MSI high phenotype has minimal numbers of LOH. 
Patients with MSI seem to have a better prognosis than patients with microsatellite 
stable (MSS) tumours (28). 
 
CIMP (CpG island methylation phenotype) 
The promoter regions of approximately 50% of all genes contain CpG islands. 
Normally, hypermethylation of these CpG islands may reflect an epigenetic mechanism 
that reinforces long-term gene silencing. In patients with CRCs of the CIMP trait, 
abnormal hypermethylation of numerous genes is seen, caused by disrupted regulation 
of DNA methylation (CIMP). If the methylation occurs at a MMR gene promoter, such 
as the MLH1 gene, the gene is silenced and the phenotype develops into a MSI type. 
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LOH 
The loosing of one of the two inherited genes of an allel is known as loss of 
heterozygosity (LOH). In tumour cells the alleles that are affected commonly contains a 
tumour suppressor gene (TSG). If the remaining allele contains a silenced TSG, via 
promoter methylation or by other mechanisms, or a mutated TSG it renders a total loss 
of function for that specific TSG, allowing for tumorous growth. In CRC, LOH at 
chromosome 18q has been associated with a poorer prognosis in stage II patents 
according to several authors (29-31). However, Carethers et al and also other 
investigators were not able to verify the importance of LOH at 18q as a prognostic 
marker in stage II CRC patients (32). 
 
Epigenetics 
Epigenetics is a broad term used to describe the regulation of gene expression due to 
mechanisms other than changes in the underlying DNA sequence. The most common 
of these mechanisms is DNA methylation in a promoter region of a gene, another being 
histone deacetylation. Regardless of the mechanism, the overall result is silencing of 
the gene, without subsequent transcription. Both environmental factors and inherited 
factors contribute to epigenetic changes (33). In colorectal cancer, hypermethylation is 
commonly seen and is associated with silencing of a number of tumour suppressor 
genes. 
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Oncogenes 
Oncogenes are mutated or over expressed normal growth-controlling genes. Oncogenes 
drive the cells to grow, divide, and protect them from programmed cell death, or 
apoptosis. Oncogenes have been shown to be an important part of the tumorigenesis in 
CRC (7,34). A few of the principal oncogenes have been discussed below. 
 
KRAS 
Ki-ras2 (Kirsten rat sarcoma viral oncogene homolog) is an oncogene that encodes a 
small GTPase transductor protein called K-ras. The gene is located on the short arm of 
chromosome 12 (12p). It is mutated in 40-50% of sporadic cases of CRC. The point 
mutations are seen in codon 12 in most cases but also at codon 13 and 61. It has been 
shown that K-ras mutations in metastatic disease are a predictor of resistance to 
Cetuximab (anti-EGFR) therapy, and, furthermore, they are associated with a worse 
prognosis of disease, as described by Lievre et al, and Font et al (29, 35, 36). Price et al, 
however, could not show any relations to VEGF and to overall survival in metastatic 
CRC patients with mutated K-ras (37). K-ras mutations together with P16 methylation 
further indicate a poorer survival according to Esteller et al (38). Fung et al and 
Bouzourene et al, could not, however, show the benefit of the K-ras mutation as a 
prognostic factor (39,40). The prognostic value depends on what kind of K-ras 
mutation a tumour has according to Winder, et al, and Senagore, et al,(41, 42). 
 
 
PIK3CA 
The PIK3CA gene encodes the p110 alpha catalytic subunit of P13K 
(phosphatidylinositol 3-kinase). Mutations in PIK3CA are thought to constitutively 
activate the AKT pathway, thereby driving cellular proliferation. PIK3CA mutations 
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have been described in 10-30% of colon cancers (43). And mutations in exon 20 have 
been associated with poorer prognosis in stage III patients (44). Other investigators 
showed poorer prognosis in patients with mutated PIK3CA only in patients with wild 
type (not mutated) K-ras (45). 
 
BRAF 
BRAF kinase is a downstream target of KRAS and activates the MAPK (mitogen-
activated protein kinase) pathway. The BRAF mutation is linked to CIMP phenotype 
(46). Tol et al, has shown that in patients with metastatic CRC, a mutated BRAF is a 
negative prognostic marker (47). 
 
Tumour suppressor genes 
The genes that operate to constrain or suppress cell proliferation are called tumour 
suppressor genes (TSG). When these genes are mutated, inactivated, or lost, they result 
in aberrant cell growth, thereby playing an important role in tumorigenesis. A few of 
the key tumour suppressor genes are described in the following. 
 
APC 
The genetic coding associated with familial adenomatous polyposis coli was identified 
in 1991 by Groden, et al., and is now called the APC gene, encoding a 2843 amino acid 
peptide(48). This TSG is located on the long arm of chromosome 5 (5q). This location 
is vulnerable, both LOH at 5q and mutations that inactivates the APC gene are common 
findings in CRC. Hsieh, et al., showed that, in blood serum taken preoperatively in 
CRC patients, mutations in APC and p53 were closely correlated with lymph node 
metastasis and the TNM stage. APC gene mutation found in serum in CRC patients is 
further associated with locoregional metastasis (49). 
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P53 
Mutations in the TP53 (tumour protein 53) gene is common in all human cancers. The 
gene is located on the short arm of chromosome 17 (17p). It is known as “the guardian 
of the genome” due to its central role in regulating the cell cycle, initiating apoptosis 
when the cell is under physical stress, inhibiting angiogenesis, and stabilizing the 
genome. Despite the obvious importance of this protein prognostic studies have not 
been conclusive. However, mutated p53 in serum is associated with peritoneal 
metastasis (49). The familial condition of inherited cancers, Li Fraumeni syndrome, has 
a p53 germ line mutation. 
 
P16 
The tumour suppressor gene p16 encodes for a cyclin-dependant kinase inhibitor, p16, 
which acts like a negative regulator of cell growth and proliferation in the G1 phase of 
the cell cycle (50). Hypermethylation of the gene p16INK4a in the mucosa in colorectal 
cancer patients is associated with reduced survival (51). 
 
MGMT 
O-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme. Promoter 
hypermethylation of the MGMT gene is thought to be an early event in carcinogenesis. 
The role in prognosis has, however, not been clearly established (52,53). 
 
PTEN 
The PTEN gene encodes a protein that is a phosphatase and tensin homolog (PTEN). 
The gene is located on the long arm of chromosome 10 (10q). It regulates the cell cycle 
and acts as an apoptotic inducer. It negatively regulates the AKT signalling pathway via 
p13K. Mutation and loss of expression of the gene is seen in both MSS and MSI 
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tumours (54). Sawai, et al, found an association between loss of expression of the 
PTEN gene and liver metastases in CRC patients (55). Loss of expression might also be 
a negative predictor to anti-EGFR treatment (56-58). The PTEN gene is a target for the 
microRNA-21 (59-62). 
 
DCC 
DCC (deleted in colorectal carcinoma) is a gene that encodes for a trans-membrane 
receptor protein. It is located on the long arm of chromosome 18 (18q). It has been 
shown to induce apoptosis, but whether or not the gene qualifies as a tumour suppressor 
gene is still under debate. Some studies have shown the potential of DCC as a 
prognostic marker, whilst others have not been able to show this (63, 64). 
 
 
 
Table 2. Some important oncogenes and tumour suppressor genes involved in CRC. 
References given in parentheses. 
  
Oncogenes Prognostic or 
predictive 
value  
found  
No 
prognostic 
value 
 
Tumour 
suppressor 
genes 
Prognostic 
Or 
predictive 
value 
found 
No 
prognostic 
value 
K-ras (29,35,36,38,41) (37,39,40) APC (49)  
PIK3CA (44,45)  P53 (49)  
BRAF (47)  P16 (51)  
   MGMT  (52,53) 
   PTEN (55-58)  
   DCC (63) (64) 
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MicroRNA 
A microRNA (miRNA) is a small non-coding RNA first discovered by Lee, et al, in 
1993 (65). To date, there have been more than 900 miRNAs discovered. After 
transcription, the pre-miRNA is cleaved twice, first in the nucleus by an enzyme called 
Drosha, and then in the cytoplasm by another enzyme called Dicer (Figure 2). The 
mature miRNA is approximately 22 nucleotides long (66). The miRNAs regulate many 
biologic processes by silencing gene expression. They act post-transcriptionally by 
forming a RISC (RNA induced silencing complex) complex that can bind to the 3´UTR 
(untranslated region) of a messengerRNA (mRNA). If the match is perfect, the mRNA 
is cleaved, and if it is imperfect, the translation is inhibited (67). The small miRNAs are 
more stable than mRNAs and are therefore promising candidates as biomarkers of 
disease. Thus, they can be extracted and analysed from frozen as well as embedded 
tissue and from serum/plasma after years of storage. MiRNAs that target TSGs are 
called oncomiRs due to their role in carcinogenesis. Alterations of the expression of 
specific miRNA have been described for many tumour types, including CRC (68-71). 
Lawrie et al, was the first to describe miRNAs in serum in cancer patients (72). A 
systematic review and meta-analysis concluded that elevated miR-21 expression did 
successfully predict poor survival in patients with a variety of carcinomas (73).  
 
Figure 2. The hairpin structured miRNA is cleaved by the enzyme Dicer and as a 
mature miRNA it binds to a messenger RNA and inhibits translation. 
 
 
 
 
 
 
miRNA 
Dicer 
AAAAA 
miRNA 
mRNA 
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Other prognostic markers 
The SMAD proteins are intracellular components of the TGF-beta signalling pathway. 
Loss of SMAD activation and/or expression occurs in approximately 10% of CRCs. 
This subset is associated with a poor prognosis (74). Carcinogenic antigen (CEA) is a 
tumour derived protein that has been used as a serological prognostic marker for many 
years. It may be most useful in the early postoperative period to help determine 
macroscopically radical tumour resection, as well as for the detection of early 
recurrence/metastases (75,76)  
 
Clinical routine 
Histopathological routine examinations and TNM classification remains the mainstay 
in our prognostic abilities. In the majority of tertiary care facilities with treatment 
centres for CRC, CEA levels are taken as a routine investigation on a regular basis. In 
additional, pathologists utilise immunohistochemistry (IHC) to detect the Kras status if 
the patient is a candidate for anti-EGFR treatment. For patients with suspected 
HNPCC, a MSI status is also examined. There is, however, a need to investigate and 
develop genetic analyses in clinical practice as a routine to improve prognosis and the 
allocation of proper adjuvant therapies on a more individualised basis. 
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2 Aims 
 
 
Study I  
To evaluate the intratumoural distribution of some genetic events of prognostic interest 
such as LOH, methylation of genes and point mutations in CRC. 
 
Study II 
To evaluate K-ras mutations, and thereby to examine the possibility to detect micro 
metastases in normal appearing lymph nodes, in stage II CRC patients and to correlate 
those to prognosis.   
 
Study III  
To screen for and determine the impact of microRNA expression levels in tumour 
tissue on the prognosis of CRC patients. 
 
Study IV 
To evaluate relative changes in the expression levels of three miRNAs (miR-21, miR-
133b and miR-185) in serum prior to, and after, radical surgery for CRC, and to further 
correlate those to prognosis. 
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3 Material/Methods 
 
Paper 1 
17 consecutive patients with CRC were included. Clinical data is shown in Table 3. 
 
Table 3. Clinical data  
Gender Female 
              Men 
9  
8  
Age       Range 
              Median 
37-88 
76 
Stage      II 
                III 
10 
7 
Localisation 
Right colon 
Left colon 
Rectum 
 
8 
5 
4 
 
 
The tumours were divided into 3 mm cubes and stored at -70 degrees Celsius. DNA 
was extracted using a Qiagen kit. Polymerase chain reaction was conducted with 
primers and tested for LOH in different loci and estimated according to Cawkwell et al 
(77). Microsatellite instability appeared as bands of varying sizes in comparison to 
normal DNA, was determined by automated analysis. 
 
Kras was amplified between codon 9 to 30, and the mutations at codon 12 and 13 were 
detected using temperature gradient gel electrophoresis (TGGE). To detect the 
methylation status for p16 gene, and MGMT gene, specific primers were used as 
shown in table 4. 
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Table 4. Methylation-specific primers for p16 and MGMT 
 Methylation specific primer-
sense 
Methylation specific primer-
antisense 
Unmethylated 
p16 
5`-TTA TTA GAG GGT GGG 
GTG GAT TGT-3` 
5`-CAA CCC CAA ACC ACA 
ACC ATA A-3` 
Methylated p16 5`-TTA TTA GAG GGT GGG 
GCG GAT CGC-3` 
5`-GAC CCC GAA CCG CGA 
CCG TAA-3` 
Unmethylated 
MGMT 
5`-TTT GTG TTT TGA TGT 
TTG TAG GTT TTT GT-3` 
5`-AAC TCC ACA CTC TTC 
CAA AAA CAA AAC A-3` 
Methylated 
MGMT 
5`-TTT CGA CGT TCG TAG 
GTT TTC GC-3` 
5`-GCA CTC TTC CGA AAA 
CGA AAC G-3` 
 
Positive and negative controls were compared with the PCR products on 2,5 % agarose 
gels. 
 
Paper II 
Ninety-nine Stage II CRC patients who underwent surgery during 1978-82 were 
included; the gender distribution was 56 men and 43 women (n=99); 27 had right-sided 
CRC, 5 had transverse CRC, 35 left-sided CRC and 32 had rectal cancer. The age range 
was 32-87 years, with a median age of 71 years. After DNA extraction from the 
tumours and the lymph nodes from the embedded tissues, Kras status was evaluated 
using the TGGE (as in paper I). Furthermore, a mini meta-analysis was done to 
compare and assess literature data in the field. 
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Paper III 
Fifty patients (26 men and 24 females) with CRC were included. The median age was  
75 (range 37-87). 15 had right-sided colon cancer, 18 left-sided colon cancer and 17 
rectal cancer. The tumours were immediately frozen and stored at -70 degree Celsius. 
Total RNA isolation was performed using the mirVana miRNA Isolation Kit (Applied 
Biosystems/ Ambion, Austin, TX). The SYBR Green-based qRT-PCR miRNA array 
platform was used for the profiling of 10 patients with distinct survival patterns (5 
patients < 50 months, 5 patients ≥ 50 months). Quantitative real-time PCR was 
performed using the Power SYBR Green Master Mix on the 7900HT Real-time PCR 
System (Applied Biosystems) employing QuantiMir universal reverse primers and 
miRNA-specific forward primers. All data values were normalized by geometric 
means of three different reference genes (Human U6, RNU43 and U1), and relative 
quantification was calculated as 2
-ΔCT
. Normalized miRNAs with <20% missing values 
were included in subsequent analyses for hierarchical clustering based on un-centered 
correlation and complete linkage using Cluster 3.0 (78) and visualized using Java 
TreeView. Significance Analysis of Microarrays (SAM) was used in order to identify 
the most significant miRNAs associated with survival. p-values were obtained for the 
Cox score statistics using the 
2 
distribution.  
 
Selected mature miRNAs were quantified using commercially available TaqMan qRT-
PCR assays (Applied Biosystems) and a 7900HT Real-Time PCR System (Applied 
Biosystems). cDNA was synthesized from 100 ng RNA using TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems) and used for quantification of miR-
133b (ID 002247), miR-185 (ID 002271), miR-320b (ID 002844), miR-21 (ID 
000397), miR-663b (ID 002857), miR-892b (ID 002214)  and miR-615-5p (ID 
002353), RNU6B (ID 001093) and miR-16 (ID 000391). Due to the low or 
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undetectable level of RNU6B expression, the expression of miRNAs was normalized 
to miR-16. All reactions were performed in triplicate, and relative expression levels 
were determined with the ΔCT method and reported as 2
-ΔCT
. 
 
Tumour samples were classified into two different groups, based on high or low 
expression of each miRNA according to the median level. The interrelationship of 
miRNAs with survival was studied using Kaplan-Meier plots, while significant 
differences between curves were evaluated using log-rank test. The significance of 
individual miRNA expression in correlation with metastasis and other clinical 
characteristics, including age, gender, stage and recurrence, was studied using Fishers‟ 
exact test. All p values obtained in this study were 2-tailed, and p-values < 0.05 were 
considered as significant. All statistical tests were performed in Statistica 8.0 (StatSoft, 
Inc., Tulsa, OK), unless otherwise stated. 
 
Paper IV 
Sixteen consecutive patients with CRC and one patient with high grade dysplastic 
adenoma were included. Blood serum was collected immediately prior to surgery and 
on the 30
th
 postoperative day, and stored at -70°C. All operations were so called R0 
(radical operations). 
 
Total RNA isolation was performed according to following protocol: 250 uL of each 
serum sample was mixed with 500 uL lysis buffer (mirVana miRNA Isolation Kit, 
Applied Biosystems/ Ambion, Ausin, TX) and 800 uL acid phenol: chloroform 
(Ambion, Austin, TX), vortexed for 30 sec, and centrifuged at 16000 rcf for 10 minutes 
at room temperature. The aqueous phase was mixed with an equal volume of acid 
phenol: chloroform and centrifuged at 16000 rcf for 10 minutes for two times at room 
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temperature. The resulting mixture was precipitated with a 0.1 volume measurement of 
3 M NaCl, 2 uL glycogen (1 mg/mL) and 2.5 volume of 100% ethanol at -20C° for at 
least 1 hour. After centrifugation at 4C° at max speed for 30 minutes, the pellets were 
air-dried at room temperature. The pellets were resuspended in 20uL elution buffer. 
RNA concentrations were measured using the NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA). Three miRs (miR-133b, miR-185 
and miR-21) were analysed using TaqMan qRT-PCR, as in paper III. 
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4 Results 
Paper I 
17 CRC tumours were divided into small cubes and the distribution of the chosen 
genetic events were examined. The distribution of the allelic loss, methylation and K-
ras-mutations in the different biopsies is shown in table 5 and 6. The K-ras mutation is 
homogeneously spread throughout the tumour, while the methylation, and in particular 
the LOH, are randomly distributed. However, LOH seems to be almost mandatory 
found in all tumours. 
  
Table 5. The number of biopsies harbouring K-ras mutations, methylation of the p16 
gene or methylation of the MGMT gene per the total number of biopsies taken from 
each tumour.  
Patient # K-ras-mut/tot p16 meth/total MGMT meth/total 
1 0/25 11/25 25/25 
2 23/23 25/25 0/25 
3 0/27 15/19 18/20 
4 0/20 16/20 16/20 
5 1/20 9/20 5/20 
6 0/33 12/19 1/19 
7 0/22 21/21 3/21 
8 15/17 18/19 13/18 
9 0/23 19/19 17/19 
10 17/17 19/19 5/19 
11 0/27 4/20 19/20 
12 17/18 17/17 12/13 
13 26/26 1/19 0/19 
14 0/20 19/20 18/20 
15 0/30 0/20 19/20 
16 19/19 8/20 0/20 
17 20/20 9/20 17/20 
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Table 6. The number of biopsies harbouring LOH per the total number of biopsies 
taken from each tumour. H = homozygotes for the chosen microsatellites; MI = 
microsatellite instability; ND = not done. 
Patient # LOH 18q LOH 17p LOH 5q 
D18S58 D18S67 D17S796 D17S1832 D5S299 D5S495 
1 1/36 25/36 19/37 33/37 2/40 2/40 
2 H 12/25 1/40 H 6/10 ND 
3 2/24 8/26 H H 14/28 12/20 
4 0/23 10/23 6/10 10/18 0/40 2/40 
5 17/40 6/39 H H 12/40 21/40 
6 8/20 14/20 14/20 H H H 
7 1/42 4/42 H 8/19 6/20 12/20 
8 6/18 H 4/18 12/18 19/38 H 
9 2/34 8/34 H 2/48 8/35 6/35 
10 H 12/20 11/20 6/20 H 14/20 
11 16/19 7/17 2/38 3/38 15/19 H 
12 15/18 8/18 14/18 H 11/17 12/18 
13 5/18 0/18 2/38 H 2/18 MI 
14 H 8/19 6/20 H 1/20 MI 
15 20/20 19/19 H 19/19 H 17/19 
16 10/18 14/18 17/20 19/20 H 0/19 
17 15/20 20/20 16/20 H 16/20 20/20 
 
 
 
Paper II 
99 patients with Stage II CRC underwent radical surgery. K-ras status from tumours, 
lymph nodes and normal mucosa were examined. 34/99 (34%) patients were found to 
harbour K-ras mutations within cancerous tissue areas, consisting of invasive cells 
microscopically. 10/34 (29%) of these were K-ras positive in the locoregional 
histologically normal appearing lymph nodes.  Conversely, all lymph nodes with K-ras 
mutations correlated to a tumour harbouring K-ras mutations. 7/10 patients with Kras 
positive lymph nodes had a relapse of the disease and died within 60 months from the 
time of primary surgical intervention. Previous studies have shown similar results when 
testing for overall effect and calculating risk ratio (79-81). These results, together with 
our results, show that the total risk of recurrence of the disease was found to be more 
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doubled (2,49) and this result for overall effect  is statistically significant (p=0.002).  
The occurrence of K-ras mutations in different specimens and the risk of developing 
metastatic disease are shown in Figure 3. The overall effect and risk of death of micro 
metastasis within the lymph nodes, according to recent studies, and including ours, is 
shown in Figure 4. 
 
 
Figure 3. The proportion of relapses among patients with or without K-ras mutations in 
tumour and locoregional lymph nodes.  
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Figure 4. Risk of relapse in colorectal cancer in relation to K-ras mutation positivity in 
the tumour and in the lymph nodes, respectively 
. 
 
Paper III 
50 patients with CRC were analysed in order to detect deregulated miRNA expression 
levels in tumour tissue. At the time of follow-up, 23 patients had succumbed to the 
disease, 14 had died of unknown or other causes and 13 were still alive. In comparison 
to the long term survival group of patients, SYBR-green test detected 7 over-expressed 
and 356 under-expressed miRNAs in the short survival group.  
 
Three over-expressed (miR-185, miR-320b and miR-663b) and three under-expressed 
miRNAs (miR-133b, miR-615-5p and miR-892b) were selected for the TaqMan test. In 
addition, we also assessed the expression level of miR-21 in the validation cohort 
because high expression of miR-21 has previously been associated with poor survival in 
CRC (73). However, we did not find any significant difference between the two groups 
based on our screening data for miR-21. 
 
Using Kaplan-Meier survival and log-rank analyses, we evaluated the association with 
overall survival for each individual miRNA expression. Patients with high expression 
of miR-185 (p=0.001; log-rank test) and low expression of miR-133b (p=0.028; log-
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rank test) were found to have a significantly shorter survival (Figure 5). They were also 
associated with metastasis. 
 No significant association was found for the other five miRNAs tested. 
 
 
 
 
low 
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Figure 5. Kaplan –Meier survival plots of patients with 
high (red) and low (blue) expression of miR-185 
(p=0.00045, log-rank test) in CRC tumour tissue. 
miR-185 
miR-133b 
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Paper IV 
17 CRC patients were included and serum was collected prior to and after surgery to 
evaluate the relative changes in three miRNAs expression levels. Clinical and follow-
up data is shown in Table 7. 
Patient   Age Gender Tumour site Stage 
Death  
Disease related 
Death 
Disease unrelated 
Adjuvant 
Chemo 
Relapse  
1  77 F Left colon 3   No No  
2  80 F Right colon 2   No No  
3  78 M Sigm/rectal 2  X No No  
4  72 F Right colon 2 X  No Liver  
5  67 M Right colon 3  X No No  
6  62 F Right colon 3   Yes No  
7  77 M Left colon 2   No No  
8  71 F Left colon (lap) 2   Yes Local recurrence 2005  
9  65 M Right colon 3   No No  
10  61 F Rectal 1   Yes Lung 2004  
11  74 F Right colon (lap) 2  X No No  
12  76 F Left colon 2 X  Yes Lung 2004  
13  68 M Left colon (lap) 3   Yes No  
14  77 M Right colon 3   Yes No  
15  71 M Left colon adenoma   No No  
16  76 M Rectal 3   Preop rad No  
17  28 M Right colon 2   No No  
Table 7. Clinical information and follow-up data 
 
All the three miRNAs evaluated were detectable in the majority of all serum samples 
(75/102; 72 %). Of these, miR-21 was the most prominent in terms of serum levels. 
However, for this specimen, there was no effect seen upon removal of the tumours in 
this series of patients as a slight, non-significant increase were detected on the 30th 
postoperative day as compared to the baseline (mean ±SEM 0.227± 0.080 
preoperatively  vs. 0.274± 0.060 postoperatively) . 
miR133b increased in one patient postoperatively. This patient later developed liver 
metastases and died from disseminated disease.  Another patient developed low levels 
of miR-133b postoperatively from undetectable levels preoperatively; this patient died 
shortly after day 30 from surgical complications. All other patients (15/17) displayed 
decreases, or undetectable levels (4/17 preoperatively; 8/17 postoperatively) of miR-
133b.  In the patient cohort as a whole, there was a significant effect of tumour 
resection on miR-133b (p=0.027). 
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Figure 6. miRNA levels preoperatively (blue) and at day 30 (red) 
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5 Discussion 
 
The results of paper I indicate an important difference in the rates and characteristics in 
the occurrence of point mutations of the K-ras gene in comparison to both allelic 
imbalances at chromosome 5, 17, and 18 and methylation of the p16 and MGMT 
genes. Allelic loss and methylation were demonstrated to occur regularly and appeared 
to be a prominent finding in advanced CRC tumours, while K-ras mutations occurred in 
approximately half of the tumours in the mutated form and were conserved as the wild-
type gene in nine of the seventeen studied cases. The standard methodology for 
characterizing genetic changes in CRC involves analysis of very limited areas of the 
tumours, using one or a few biopsies (39, 40, 82-86). However, these tumours generally 
display a morphologically mosaic-like pattern, representing different intra-tumour sub- 
clones of cancer development. Thus, biopsies for DNA aberrations that are 
heterogeneously distributed throughout tumours as shown here could result in uncertain 
and even clinically irrelevant data. This may also contribute to the variability in the 
importance of certain markers as indictors of prognosis.  
 
K-ras mutations, when present, are found early in the adenoma – carcinoma sequence 
(25) with a proportion of K-ras mutations in studies of colonic adenomas similar to 
those of carcinomas (29, 39, 40, 87, 88).  From our results, with only 3/17 tumours not 
containing homogeneously mutated or wild-type K-ras, one may conclude that this 
early event appears to be strikingly preserved throughout clonal expansion and tumour 
progression in CRC. 
At present the decision to use anti-EGFR therapy in metastatic CRC is based on the K-
ras status and this study is supportive of the use of a single biopsy to predict treatment 
responsiveness (18-20). 
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In the second study, we were able to detect the occurrence of mutated K-ras in DNA 
from microscopically normal loco-regional lymph node tissue in stage II CRC patients. 
In this case it might be harder to use just one biopsy from the lymph node, since there 
may be just a few tumour cells that contain the mutation. TGGE is considered to be a 
sensitive method and therefore a useful tool to detect a few cells with mutations among 
the abundance of K-ras wild type cells. In our study, this finding of occult metastases 
correlated to a worsened prognosis in terms of metastatic relapse and disease specific 
mortality. 
  
In routine clinical practice, identification of metastatic cancer cells in regional lymph 
nodes by microscopic investigation is one of the most significant prognostic factors in 
the staging process (89-91). Stage II cancer, representing the finding of pathologically 
normal loco-regional lymph nodes, usually correlates to a relatively good prognosis, 
though approximately 20-30 percent will eventually die from metastatic disease (89).  
 
Mutation of the K-ras gene as a disease marker in healthy lymph nodes and detected in 
10/99 of the cases we studied, appears to be predictive of an increased risk of 
developing disease recurrence and disease related mortality. 7 out of the10 patients 
(70%) later developed recurrent disease; either through local relapse or metastases. The 
lack of statistical significance (p=0.07) may be due to the relatively small number of 
patients and the small number of lymph nodes.  However, by combining recent and 
similar research in the field of occult lymph node disease, it is possible to demonstrate a 
significantly higher risk ratio (2,5 times, p=0.002) of developing metastases and relapse 
in the disease (79-81).  
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34 of the 99 CRC patients that we analysed in our study had K-ras mutations in the 
invasive cells of the tumour specimen. This frequency is similar to that of previously 
reported for K-ras mutations in CRC tumours (29, 80, 92, 93). Our results suggest that 
adding molecular techniques may add sensitivity to the microscopic examination and 
may be a valuable supplement in the efforts of sub-classifying patients with stage II 
CRC. 65 of the 99 patients did not show K-ras mutations in their tumour specimens. 
However, by the addition of other genetic analyses in locoregional lymph nodes we 
may increase our ability to identify subgroups of Stage II CRC patients which in turn 
could benefit from adjuvant treatment. 
 DNA is stable and therefore suitable as a biomarker but there seems to be a difference 
between the representativeness of the different DNA and chromosomal changes in the 
tumour. MicroRNA is, as mentioned previously, a recently discovered small RNA that 
appears to have potential to become useful as a biomarker; due to its stability and free 
circulation in blood. 
 In the third study we focused on miRNAs. The deregulation of two miRNAs (miR-185 
and miR-133b) correlates with patient survival and metastasis, suggesting that these 
miRNAs (or their targets) may have prognostic implications in CRC. In tumour tissue, 
miR-185 has been found to inversely correlate to PTPN13 (protein tyrosine 
phosphatase, non-receptor type 13), a putative tumour suppressor gene that can 
suppress cell growth and induce apoptosis (94, 95). However, the role of miR-185 is 
somewhat complex as it appears to target different genes in different cell types, 
contribute to different biological processes, and may even act in a tumour suppressing 
way in certain cancer cell lines (96).  
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Low expression of miR-133b is associated with poor survival and metastasis among 
CRC patients in our study. miR-133b is down-regulated in several other cancer types, 
including colorectal cancer,(97), lung cancer,(98) bladder cancer,(99) gastric 
cancer,(100) esophageal squamous cell carcinoma (101) and squamous cell carcinoma 
of tongue(102). In addition, miR-133b has been reported to have a prognostic potential 
in bladder cancer (103).  
The expression of miR-21 is reportedly increased in many tumour types, including 
CRC, and its up-regulation has been associated with tumour cell invasive abilities, poor 
survival and the suppression of tumour suppressor proteins (104, 105). Interestingly, 
Nielsen et al. observed that the expression of miR-21 was predominantly found in 
fibroblast-like cells located in the stromal compartment of the colon tumours. 
 miR-21 has also been related to remodelling of extra cellular matrix and associated 
with cellular motility and key enzymes in extra cellular matrix breakdown (106).  
Since its emergence as an important regulator in the control of many cell functions, 
miR-21 has been extensively studied in various fields including angiogenesis, aging and 
wound healing (107). 
However, we did not observe a significant difference in expression levels between the 
long and short survival groups of CRC patients using both SYBR-green and TaqMan 
qRT-PCR assays.  
 
Circulating miRNAs exist and are stable in human serum and plasma and are much less 
susceptible to degradation of nucleases than RNA. These properties make them highly 
attractive as serum markers (108). We therefore investigated miR-185, miR-133b and 
miR-21 as potential novel non-invasive serum biomarkers for the prognosis of CRC 
patients following surgery.  
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In the forth study we did not find any correlation between the serum baseline levels of 
miR-21, miR-133b, or miR-185 and the risk of recurrent disease in CRC patients. In 
addition, there was no correlation between intra-individual changes in serum levels and 
disease outcome. The levels in serum of mir-21 were not affected by radical tumour 
resection. However, there was a significant decrease in the level of miR-133b among 
the patients following surgery, declining or being undetectable in 15/17 patients. 
Furthermore, an overall reduction for miR-185 was also seen. 
 
Circulating tumour-specific nucleic acids as biomarkers for the early detection of CRC, 
and other tumours, would present a patient-friendly, non-invasive alternative to current 
screening procedures. This method could also serve as a convenient predictive tool in 
judging the effects of treatment and the monitoring of the individual patient‟s need of 
surveillance.  In a previous report, the prognostic value of serum analysis of circulating 
mutated K-ras in CRC patients was evaluated (109). A wide array of investigations 
looking at the value of mutational analysis of DNA, mRNA and epigenetic events in 
plasma and serum have been studied, though the impact on clinical implications is as 
yet unclear (110). The different mRNA targets and the function of many miRNAs have 
been intensively explored over the last years, with emphasis on their role in neoplastic 
development. Each miRNA may potentially regulate the expression of tens to hundreds 
of protein-coding genes, though different miRNA are specific to different tissues.  In 
both our studies, miR-21 levels were not significantly deregulated and did not show any 
prognostic value. This finding strongly indicates that a substantial part of this miRNA 
in the serum of CRC patients does not originate from loss or secretion from the cancer 
cells. Thus, the results may well indicate that a multitude of cells, including fibroblasts, 
involved in the postoperative healing and remodelling processes may be the source of 
miR-21 during serum sampling postoperatively. The absence of serum from healthy 
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controls having undergone surgery for benign disease in this study precludes 
conclusions on the relative role of tumour cells preoperatively and fibroblasts and other 
cell types involved in the healing process postoperatively. 
 
The mean postoperative levels in serum of miR-185 are decreased in this study. This 
may reflect a major depletion of the cells and source of miR-185 origin after radical 
surgery. The ambiguous biological role of miR-185 and the fact that a few patients 
(4/17) showed elevations in their serum levels postoperatively indicates that larger 
studies are needed to explore the prognostic significance of miR-185 in serum. 
The expression of miR133b in serum is significantly decreased with tumour removal in 
this patient cohort. However, the role of miR-133b and its targets in CRC progression 
remains to be further investigated. 
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6 Conclusions 
- LOH 5q, 17p, and 18q, and methylation of MGMT and p16, are unevenly 
distributed throughout CRC tumours and of limited value as prognostic markers 
if derived from single biopsies.  
- K-ras mutations are evenly distributed throughout CRC tumours, in line with 
the concept that they appear early in tumour development. 
- K-ras mutations can be found in histologically healthy lymph nodes and seem 
to predict a worse prognosis in Stage II patients with this finding. 
- Low expression of miR-133b and high expression of miR-185 in CRC tumours 
are associated with poor survival and the development of disseminated disease. 
- The level of miR-21 in blood serum is not affected by radical surgery for CRC. 
- The level of miR-133b in blood serum is significantly reduced after radical 
surgery for CRC. 
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7 Future perspectives 
The pathological anatomical diagnosis (PAD) continuously improves. Still, there is a 
need for better tools to assess prognosis and direct appropriate treatment to the right 
patient. A future way to meet these needs may be the use of standardized set of 
molecular diagnostic analyses. The work in this thesis points out some of the molecular 
events surrounding tumorigenesis in CRC and further suggests the potential use of 
certain molecules as biomarkers, either for diagnosis and prognosis, or as an aid in 
assessing the need for adjuvant therapy. Though a fair amount of pre-clinical studies 
have been conducted, this has yet to be translated into clinical practice. The solution is 
multifactorial. The current evidence level is rather poor due to the limited number of 
patients in several studies, the lack of sub-groups, and limited number of biopsies. 
These factors all lead to contradictory results and low reproducibility. The costs and 
time-consuming laboratory work also make it difficult to integrate molecular analyses 
as a clinical routine, despite promising data. At present, immunohistochemistry (IHC) 
is used routinely to detect K-ras mutations in metastatic CRC to predict response to 
anti-EGFR treatment. However, IHC has limitations in sensitivity (111) and can 
presumably not be used to detect abnormal K-ras in normal appearing lymph nodes.  
 
Malignant cells follow a Darwinian selection and one key question is which molecular 
events are critical for the tumour to metastasize. To understand this, further molecular 
studies based on clinical material and outcome data are needed. Since cancer in many 
ways is a heterogeneous disease, many questions cannot be answered through studies of 
standardized in vitro cell lines, and thus there is a need for translational collaborative 
efforts between preclinical scientists and clinicians. Metastases may be more 
homogenous than the primary tumour due to clonal expansions, but on the other hand a 
metastasis is aggressive and the turn-over rate is high, making it likely that the mutation 
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rate is also high. In our first paper we have demonstrated the need to examine the whole 
tumour to evaluate interesting genetic or molecular events as potential biomarkers. This 
needs to be further characterized also in metastases. 
  
In breast cancer surgery, the use of sentinel nodes is very important, but this far sentinel 
node studies in CRC have not been without contradictions. We have shown that the 
findings of micro metastases in healthy lymph nodes (indirectly by looking at K-ras 
mutations) indicate a worse prognosis in CRC patients. Since the micro metastases can 
easily “drown” in different analytic approaches, as the majority of the cells are 
unaffected, the challenge is to find a sensitive and specific tool that is not too costly and 
time-consuming. There is a need to further evaluate the detection of sentinel nodes also 
in CRC, and perhaps blue staining is enough (112) and would make it easier to detect 
micro metastases.  
 
MicroRNA is a promising potential biomarker. In a near future, the development of 
high through-put techniques based on microchips may become available detecting 
different expression profiles. To be able to properly utilize these tools, further 
development of our ability to correlate these findings to outcome will be needed. Thus, 
as clinicians, we will need to establish standard patients sub-groups based on molecular 
tumour analyses and evaluate how these groups behave in relation to prognosis and 
individualised treatments. 
 
The reasons why a biomarker becomes over- or under-expressed are multifactorial and 
still in general often unresolved. It may be due to loss or gain of parts of a chromosome, 
epigenetic silencing, single nucleotide mutations or other mechanisms, in turn causing 
deregulation. For a clinician the question is always how we can apply new basic 
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knowledge in clinical practice. Can we use it as a diagnostic, prognostic or a predictive 
marker that is both sensitive and specific? Can we develop an anti-drug that is safe and 
without side-effects? How much would it cost and how time-consuming would it be to 
use it? How many patients would benefit from using this new biomarker? There are 
still many unanswered questions. In summary, this thesis is a small piece in the large 
puzzle and may bring us one step closer to finding the answers. 
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Swedish summary/Svensk populärvetenskaplig 
sammanfattning 
 
Tjock- och ändtarms cancer är en mycket vanlig sjukdom i västvärlden. I Sverige är det 
den tredje vanligaste cancer sjukdomen för män och kvinnor. Nästan hälften av dem 
som insjuknar dör på grund av sjukdomen. Behandlingen består av operation och i 
vissa fall cellgifter och strålning. För att ta reda på vilket stadium patienten är i görs 
utredningar med hjälp av röntgen undersökningar före operationen. Efter operationen 
görs mikroskopisk undersökning av preparatet och då får man en säkrare 
stadieindelning. Stadium II betyder att det inte finns någon mikroskopiskt synlig 
tumörväxt i närliggande lymfkörtlar som tas med preparatet. I stadium III finns det växt 
i lymfkörtlar och det betyder oftast att patienten blir aktuell för cellgiftsbehandling. 
Tyvärr är denna indelning inte hundra procent säker och det innebär att vissa i stadium 
II inte får cellgifter, fast det skulle behöva det, samt att vissa med stadium III får 
cellgifter fast de inte behöver. För att kunna utveckla en säkrare diagnos, prognos och 
även kunna individualisera tex cellgiftsbehandlingen, behövs fler genetiska analyser, 
som kan ge mer exakta svar.  Denna avhandling består av 4 olika arbeten som har 
försökt utveckla den genetiska analysen vid tjock- och ändtarmscancer (kolorektal 
cancer). 
 
I arbete I, analyserades tumörer från 17 patienter som opererats för kolorektal cancer. 
Tumörerna delades i mycket små bitar och undersöktes på förekomsten av genetiska 
förändringar. De förändringarna var mutationer i en oncogen (gen som driver tillväxt av 
cell, kan liknas vid en ”gaspedal”) som heter K-ras, metylering av 2 olika gener samt 
förlusten av vissa delar av kromosomer. Metylering innebär att en gen blir ”tystad” och 
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inte längre uttrycks (kan liknas vid att ett hänglås ”låser” genen). Analyserna visade att 
K-ras mutationerna var jämnt spridda i hela tumören, medan de andra förändringarna 
var mycket ojämnt fördelade i tumören, men nästan alltid till sist hittades i någon liten 
bit. Detta innebär att man kan lita på en liten biopsi (provbit) när man letar efter K-ras 
mutation, men när det gäller andra genetiska förändringar måste man kontrollera 
förekomsten noggrant först. Detta är viktigt, då man har visat att en typ av cellgift inte 
har effekt om man har K-ras mutation.  
 
I arbete II, undersöktes lymfkörtelvävnad och tumörvävnad från 99 patienter som var 
opererade för kolorektal cancer. Man hade bedömt att lymfkörtlarna var friska när man 
undersökte dem mikroskopiskt. Förekomsten av K-ras mutationer analyserades både i 
tumörerna och i lymfkörtlarna. Resultatet blev att 34/99 hade K-ras mutationer i 
tumören och av dessa hade 10 stycken det även i lymfkörtlarna. 7 patienter av dessa 10 
(70 %) fick tillbaka sjukdomen i någon form (antingen lokalt eller som metastas 
(dottertumör) i lever eller lunga). Vid jämförelse av tidigare liknande studier noterades 
att det föreligger en ökad risk för återfall, dvs en sämre prognos hos de patienter med 
mutationer i lymfkörtlar som mikroskopiskt sett ser friska ut. 
 
I arbete III, undersöktes 50 patienters tumörer med avseende på så kallade mikroRNA. 
MikroRNA bildas från DNA och därefter påverkar mikroRNA generna genom att 
binda till messenger RNA (RNA är ”modell” för protein byggande). Det leder till att 
proteinet i fråga inte kan byggas. Först undersöktes 10 patienter, där 5 hade dött tidigt 
och 5 fortfarande levde efter sin operation. Några mikroRNA upptäcktes som hade 
olika mängd i de 2 grupperna. 6 stycken av dessa valdes ut och nivån hos dessa 
kontrollerades hos alla 50 patienter. Resultaten visade att mikroRNA-133b var lågt och 
mikroRNA-185 var högt hos de med dålig prognos= kort överlevnad. 
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I arbete IV undersöktes mikroRNA-133b, mikroRNA-185 och även mikroRNA-21 i 
blodet hos 16 patienter med kolorektal cancer och 1 patient med adenom (polyp) i 
tjocktarmen. Blodprov togs precis före operation och 30 dagar efter operation. Ingen 
förändring kunde noteras avseende nivåer av miR-21 före och efter operation, men 
miR-185 hade tendens att sjunka och miR-133b sjönk signifikant efter operation. Ingen 
korrelation till prognos kunde ses. Bedömningen blev därmed att miR-133b samt miR-
185 kan var intressanta ur biomarkör synpunkt, men att miR-21 sannolikt utsöndras 
från andra celler än tumörceller, t.ex. bindvävsceller. 
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